HIV-1患者每周4天维持治疗策略中抗逆转录病毒药物血浆浓度(ANRS 170-Quatuor试验)
ANRS-170-QUATUOR研究将患者随机分为每周服药4天停3天(4/7)组或连续治疗(7/7)组,监测血浆抗逆转录病毒浓度至48周,之后全部转为4/7策略随访至96周。结果显示4/7组在服药期结束时药物浓度接近连续治疗,停药期末浓度较低。
要点
- 4/7组在连续服药4天后抗逆转录病毒血药浓度接近连续治疗。
- 停药期末所有药物浓度显著降低,除拉替拉韦和阿扎那韦外。
- 第0周两组浓度可比,除拉替拉韦在4/7组较高外,均高于治疗药物监测通常推荐的有效值。
核心结论
- 4/7天治疗选项在连续服药四天后产生接近连续治疗的抗逆转录病毒血药浓度,在非治疗期末浓度较低。
研究设计与样本
- ANRS-170-QUATUOR研究将患者随机分为两组,分别接受每周服药4天停3天(4/7)或连续治疗(7/7)的三联疗法,监测血浆抗逆转录病毒浓度至48周,之后全部转为4/7策略随访至96周。
主要发现
- 第0周两组测量浓度可比,除拉替拉韦在4/7组较高外,所有浓度均高于治疗药物监测通常推荐的有效值。
- 服药期两组中位浓度比较显示,利匹韦林在4/7组为88 ng/mL(四分位距64-112),7/7组为130 ng/mL(82-160),P < 0.001。
- 替诺福韦二吡呋酯在4/7组为93 ng/mL(73-135),7/7组为117 ng/mL(83-160),P < 0.001;替诺福韦艾拉酚胺在4/7组为11 ng/mL(7-15),7/7组为14 ng/mL(11-18),P = 0.001。
- 第48周分析时,除拉替拉韦(P = 0.493)和阿扎那韦(P = 0.105)外,所有药物停药期中位浓度显著降低(P < 0.001),拉替拉韦和阿扎那韦的患者数非常少。
局限性
- 拉替拉韦和阿扎那韦的患者数非常少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Charaterization of the plasma concentrations of antiretrovirals in a 4-days-a-week maintenance treatment strategy in the ANRS-170-QUATUOR study. METHODS: Patients were randomized in two groups receiving triple therapy taken 4-days-ON and 3-days-OFF (4/7) or continuous therapy (7/7). Plasma antiretroviral concentrations were monitored during the 'ON-treatment period' (Day 3 or 4 of the 4-day treatment block) and the 'OFF-treatment period' (Day 3 of the 3-day drug cessation) for the 4/7 group, or before the daily drug intake for the 7/7 group, until week-48 (W48). After W48, all patients switched to the 4/7 strategy and were followed until W96. RESULTS: W0 measured concentrations were comparable in both groups, except for raltegravir, concentrations of which were higher in the 4/7 group, and were all above the values usually recommended to be effective in therapeutic drug monitoring. Comparison of ON-period median concentrations between the two groups showed a statistical difference for rilpivirine [88 ng/mL (interquartile range (IQR) = 64-112) for 4/7 arm versus 130 ng/mL (82-160) for 7/7 arm, P < 0.001] and tenofovir [tenofovir disoproxil fumarate: 93 ng/mL (73-135) for 4/7 arm versus 117 ng/mL (83-160) for 7/7 arm, P < 0.001; tenofovir alafenamide: 11 ng/mL (7-15) for 4/7 arm versus 14 ng/mL (11-18) for 7/7 arm, P = 0.001]. Median OFF concentrations were significantly lower (P < 0.001) at the 48 week analysis for all medications except for raltegravir (P = 0.493) and atazanavir (P = 0.105), for which the numbers of patients were very small. CONCLUSIONS: The 4/7-day treatment option led to antiretroviral blood levels close to continuous treatment after the four consecutive days of medication, and to low levels at the end of the non-treatment period.
引用
- Abe E, Landman R, Assoumou L, et al. Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial). J Antimicrob Chemother. 2024. PMID: 38656448. doi:10.1093/jac/dkae112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。